Using AI to improve treatment for liver tumors
Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors Within the IMAGIO Project (A-IMAGIO)
This study is testing whether using artificial intelligence can help doctors choose the best treatments and predict outcomes for patients with liver tumors undergoing thermal ablation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years to 110 Years |
| Sex | All |
| Sponsor | Leiden University Medical Center Academic / other |
| Locations | 1 site (Leiden) |
| Trial ID | NCT06179602 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop and validate algorithms that utilize artificial intelligence and machine learning to enhance patient selection, treatment planning, and outcome prediction for individuals undergoing thermal ablation of malignant liver tumors. Over a four-year period, the study will collect comprehensive data on patient demographics, tumor characteristics, and treatment details, along with imaging before, during, and after the procedure. The ultimate goal is to establish thermal ablation as the preferred treatment for most patients with primary or secondary liver tumors through a standardized and accessible workflow.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are deemed suitable for percutaneous thermal liver ablation following a multidisciplinary tumor board discussion.
Not a fit: Patients who are unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve treatment outcomes for patients with liver cancer by optimizing the use of thermal ablation.
How similar studies have performed: Other studies have shown promise in using AI for treatment optimization in oncology, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or above * Candidate for percutaneous thermal liver ablation as discussed in a multidisciplinary tumorboard (MDT) * Informed consent Exclusion Criteria: * Patients lacking capacity to give informed consent.
Where this trial is running
Leiden
- Leiden University Medical Centre — Leiden, Netherlands (Recruiting)
Study contacts
- Principal investigator: Mark C. Burgmans, MD PhD — Leiden univeristy medical centre
- Study coordinator: Coosje A. M. Verhagen, Drs.
- Email: c.a.m.verhagen@lumc.nl
- Phone: +31-71-5264376
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.